


Topoisomerase II α -IN-4

Cat. No.:	HY-151453
CAS No.:	2860554-26-1
Molecular Formula:	C ₂₅ H ₂₁ NO ₂
Molecular Weight:	367.44
Target:	Topoisomerase; Apoptosis
Pathway:	Cell Cycle/DNA Damage; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Topoisomerase II α -IN-4 (F2) is a non-intercalative ATP-competitive human DNA topoisomerase II inhibitor with an IC ₅₀ value of 3.8 and 10.1 μ M for TopoII α and TopoII β , respectively. Topoisomerase II α -IN-4 shows potent potency in apoptosis induction and cell cycle arrest in HepG2 cells. Topoisomerase II α -IN-4 exhibits strong antitumor activities against human cancer cell lines, it can be used for the research of cancer ^[1] .																	
IC₅₀ & Target	topoisomerase II alpha 3.8 μ M (IC ₅₀)	topoisomerase II beta 10.1 μ M (IC ₅₀)																
In Vitro	<p>Topoisomerase IIα-IN-4 (0-50 μM; 72 h) shows antiproliferative activities against cancer cells^[1]. Topoisomerase IIα-IN-4 shows high inhibitory activity and subtype selectivity against TopoIIα and β with IC₅₀s of 3.8 and 10.1 μM, respectively^[1]. Topoisomerase IIα-IN-4 (0.3 μM; 4 h) is a non-intercalative TopoIIα catalytic inhibitor^[1]. Topoisomerase IIα-IN-4 (0.5-1 μM; 48 h) induces cell apoptosis^[1]. Topoisomerase IIα-IN-4 (0.5-1 μM; 24 h) induces cell-cycle arrest^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Proliferation Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>HeLa, HCT-116, MDA-MB231, HepG2, A549, CCL-226, BEAS-2B and HL-7702 cell lines</td> </tr> <tr> <td>Concentration:</td> <td>0-50 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>72 hours</td> </tr> <tr> <td>Result:</td> <td>Inhibited HeLa, HCT-116, MDA-MB 231, HepG2, A549, CCL-226, BEAS-2B and HL-7702 cells with IC₅₀s of 0.1, 0.2, 0.3, 0.2, 0.3, 0.3, ∞50, 31.9 and 16.7 μM, respectively.</td> </tr> </table> <p>Western Blot Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>HepG-2 cell line</td> </tr> <tr> <td>Concentration:</td> <td>0.3 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>4 hours</td> </tr> <tr> <td>Result:</td> <td>Showed no effect on the level of phospho-histone H2AX.</td> </tr> </table>		Cell Line:	HeLa, HCT-116, MDA-MB231, HepG2, A549, CCL-226, BEAS-2B and HL-7702 cell lines	Concentration:	0-50 μ M	Incubation Time:	72 hours	Result:	Inhibited HeLa, HCT-116, MDA-MB 231, HepG2, A549, CCL-226, BEAS-2B and HL-7702 cells with IC ₅₀ s of 0.1, 0.2, 0.3, 0.2, 0.3, 0.3, ∞ 50, 31.9 and 16.7 μ M, respectively.	Cell Line:	HepG-2 cell line	Concentration:	0.3 μ M	Incubation Time:	4 hours	Result:	Showed no effect on the level of phospho-histone H2AX.
Cell Line:	HeLa, HCT-116, MDA-MB231, HepG2, A549, CCL-226, BEAS-2B and HL-7702 cell lines																	
Concentration:	0-50 μ M																	
Incubation Time:	72 hours																	
Result:	Inhibited HeLa, HCT-116, MDA-MB 231, HepG2, A549, CCL-226, BEAS-2B and HL-7702 cells with IC ₅₀ s of 0.1, 0.2, 0.3, 0.2, 0.3, 0.3, ∞ 50, 31.9 and 16.7 μ M, respectively.																	
Cell Line:	HepG-2 cell line																	
Concentration:	0.3 μ M																	
Incubation Time:	4 hours																	
Result:	Showed no effect on the level of phospho-histone H2AX.																	

	Apoptosis Analysis ^[1]	
	Cell Line:	0.5-1 μ M
	Concentration:	0.3 μ M
	Incubation Time:	48 hours
	Result:	Increased the total numbers of early and late apoptotic cells from 6.0% to 70.6% at the concentration of 1 μ M.
In Vivo	Topoisomerase II α -IN-4 (500 mg/kg; p.o. twice at the first day) shows no acute toxicity in vivo ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	C57BL/6 mice ^[1]
	Dosage:	500 mg/kg
	Administration:	Oral gavage; 500 mg/kg twice at the first day
	Result:	Exerted lower toxicity in this established test and caused no significant difference of body weight of mice.

REFERENCES

[1]. Xu G, et al. Discovery of 1,2-diphenylethene derivatives as human DNA topoisomerase II catalytic inhibitors and antitumor agents. Eur J Med Chem. 2022 Aug 26;243:114706.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA